Korean J Gastrointest Endosc.
2004 May;28(5):230-236.
A Phase III Clinical Trial of Stillen(TM) for Erosive Gastritis
- Affiliations
-
- 1Department of Gastroenterology, Inje University College of Medicine, Busan, Korea.
- 2Department of Gastroenterology, Ulsan University College of Medicine, Seoul, Korea.
- 3Department of Gastroenterology, Chunnam University College of Medicine, Gwangju, Korea.
- 4Department of Gastroenterology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract
- BACKGROUND/AIMS
Phase IIb clinical study of Stillen(TM), a novel cytoprotectant, for gastritis showed 180 mg of Stillen, t.i.d. for 2 weeks results in a significant increase of cure rate when compared with a placebo group. It is reported that antioxidative effect and strengthening the endogenous cytoprotective molecules of the gastric mucosa play a pivotal role for cytoprotective action of Stillen(TM). The aim of this phase III multicenter, double-blind comparative study was to assess the efficacy of Stillen(TM) for the treatment of erosive gastritis.
METHODS
Five hundred and twelve patients with erosive gastritis were enrolled and divided into three groups. Each group received 180 mg or 360 mg of Stillen(TM) or 600 mg of cetraxate (Neuer(TM)) t.i.d. for 2 weeks, respectively and a follow-up endoscopic examination for evaluation.
RESULTS
Patients treated with 180 mg and 360 mg of Stillen(TM) had a significantly improved endoscopic cure rate of gastritis (55.6% and 57.5%, respectively) compared with patients treated with 600 mg of cetraxate (35.5%, p<0.001). Endoscopic improvement rate was also significantly higher in 180 mg group (67.3%) and 360 mg group (65.0%) of Stillen(TM) treated patients than cetraxate treated group (46.4%, p<0.001). During the study, both Stillen(TM) and cetraxate were well tolerated.
CONCLUSIONS
These results clearly demonstrate that Stillen(TM) is an efficacious, safe, and well-tolerated treatment for gastritis.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of Albis(R) in Acute and Chronic Patients with Gastritis: A Double-blind, Placebo-controlled, Randomized Multi-center Study
- Case-Control Study on Effects of Alcohol Intake and Smoking to Gastritis of Korean Adult Men
- Single Blinded, Randomized, Active Drug Comparative, Multi-center Study to Evaluate the Therapeutic Efficacy of Gliptide(R)Tab (Sulglycotide 200 mg) in Gastritis Patients; Phase IV Study
- The Effect of Cimetidine in Treatment of Erosive Gastritis
- Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, DoubleBlind, Active Control, Noninferiority, Multicenter, Phase 3 Study
